IDEAYA Biosciences, Inc.
darovasertib
metastatic uveal melanoma
Countdown
177days
Catalyst readout · ~ Dec 31, 2026 estimated
What's at stake
A key catalyst for darovasertib (metastatic uveal melanoma) is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Based on these data, the Company will target to submit an NDA to the U.S. Food and Drug Administration (“FDA”) in the second half of 2026.”